Evidence map›Paper›PMID 42400865›Full record

ArticleCEN case reports2026

Immunoglobulin A nephropathy with superimposed minimal change disease complicated by acute kidney injury requiring temporary hemodialysis.

Yuki Nagaike, Akifumi Tabei, Yu Shimizu, Shiori Mori, Hiroyuki Mori, Kengo Yoshida, Yoshinori Takei, Satoshi Furukata, Katsuhiko Takara, Nozomi Kadota and 5 more

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuki Nagaike *Department of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Akifumi Tabei *Department of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan. eetabei@gmail.com.ORCID 0009-0007-3941-6432
Yu ShimizuDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Shiori MoriDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Hiroyuki MoriDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Kengo YoshidaDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Yoshinori TakeiDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Satoshi FurukataDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Katsuhiko TakaraDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.
Nozomi KadotaDepartment of Nephrology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku,Tokyo, 113-8421, Japan.
Kazuaki MoriDepartment of Nephrology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku,Tokyo, 113-8421, Japan.
Shoki IkedaDepartment of Nephrology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku,Tokyo, 113-8421, Japan.
Muneharu YamadaDepartment of Nephrology, Tokyo Medical University Hachioji Medical Center, 1163 Yakatamachi, Hachioji, Tokyo, 193-0998, Japan.
Yusuke SuzukiDepartment of Nephrology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku,Tokyo, 113-8421, Japan.
Noriaki HemmiDepartment of Nephrology, Fukaya Red Cross Hospital, 5-8-1 Kamishibachonishi, Fukaya, Saitama, 366-0052, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin A (IgA) nephropathy (IgAN) with superimposed minimal change disease (MCD) is a rare but increasingly recognized clinicopathological phenotype that is generally associated with a favorable renal prognosis. We present a case of IgAN with MCD complicated by severe acute kidney injury (AKI) during the clinical course and requiring temporary renal replacement therapy. A 38-year-old man presented with acute nephrotic syndrome. Renal biopsy showed mesangial IgA deposition, and anti-galactose-deficient IgA1 antibody (KM55) staining demonstrated co-localization with IgA deposits, supporting the diagnosis of IgAN with superimposed MCD. Electron microscopy revealed foot process effacement, leading to a diagnosis of IgAN with MCD. High-dose prednisolone therapy was initiated; however, the patient subsequently developed severe AKI requiring hemodialysis (HD). Concurrent treatment with cyclosporine A and steroid pulse therapy was administered, ultimately allowing successful discontinuation of HD. This rare case was diagnosed as IgAN with MCD based on mesangial IgA deposition supported by KM55 staining and characteristic electron microscopic findings, and this case demonstrates that severe AKI requiring temporary HD may occur during the clinical course of IgAN with MCD. Although IgAN with MCD has been increasingly recognized, reports of cases complicated by severe AKI requiring HD remain limited in the literature. This patient showed subsequent improvements in renal function and proteinuria, suggesting that this condition may be reversible. These findings highlight the importance of careful clinical management with attention to the potential risk of AKI even in patients with IgAN with MCD.

Indexed as

Acute Kidney InjuryGlomerulonephritis, IGANephrosis, LipoidRenal DialysisAdultBiopsyCyclosporineHumansImmunoglobulin AMaleMicroscopy, ElectronPrednisoloneCyclosporineImmunoglobulin APrednisoloneAKIGalactose-deficient IgA1HDIgANIgAN with MCDKM55

Identifiers

PMID42400865
PMCPMC13332906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.